Alpha 2 delta (α2δ) ligands, gabapentin and pregabalin

What is the evidence for potential use of these ligands in irritable bowel syndrome

Jeremy D. Gale, Lesley A. Houghton

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Irritable bowel syndrome (IBS) is a complex disorder that is characterized by abdominal pain and altered bowel habit, and often associates with other gastrointestinal symptoms such as feelings of incomplete bowel movement and abdominal bloating, and extra-intestinal symptoms such as headache, dyspareunia, heartburn, muscle pain, and back pain. It also frequently coexists with conditions that may also involve central sensitization processes, such as fibromyalgia, irritable bladder disorder, and chronic cough. This review examines the evidence to date on gabapentin and pregabalin which may support further and con- tinued research and development of the α2δ ligands in disorders characterized by visceral hypersensitivity, such as IBS. The distribution of the α2δ subunit of the voltage-gated cal- cium channel, possible mechanisms of action, pre-clinical data which supports an effect on motor-sensory mechanisms and clinical evidence that points to potential benefits in patients with IBS will be discussed.

Original languageEnglish (US)
Article numberArticle 28
JournalFrontiers in Pharmacology
VolumeJUN
DOIs
StatePublished - 2011

Fingerprint

Irritable Bowel Syndrome
Ligands
Central Nervous System Sensitization
Dyspareunia
Heartburn
Fibromyalgia
Myalgia
Calcium Channels
Back Pain
Cough
Abdominal Pain
Habits
Headache
Hypersensitivity
Emotions
Urinary Bladder
Research
Pregabalin
gabapentin

Keywords

  • αδ ligands
  • Central sensitization
  • Gabapentin
  • Irritable bowel syndrome
  • Motility
  • Peripheral sensitization
  • Pregabalin
  • Visceral sensitivity

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Alpha 2 delta (α2δ) ligands, gabapentin and pregabalin : What is the evidence for potential use of these ligands in irritable bowel syndrome. / Gale, Jeremy D.; Houghton, Lesley A.

In: Frontiers in Pharmacology, Vol. JUN, Article 28, 2011.

Research output: Contribution to journalArticle

@article{c06cb0bea3984579a9d62710e1d0c6d9,
title = "Alpha 2 delta (α2δ) ligands, gabapentin and pregabalin: What is the evidence for potential use of these ligands in irritable bowel syndrome",
abstract = "Irritable bowel syndrome (IBS) is a complex disorder that is characterized by abdominal pain and altered bowel habit, and often associates with other gastrointestinal symptoms such as feelings of incomplete bowel movement and abdominal bloating, and extra-intestinal symptoms such as headache, dyspareunia, heartburn, muscle pain, and back pain. It also frequently coexists with conditions that may also involve central sensitization processes, such as fibromyalgia, irritable bladder disorder, and chronic cough. This review examines the evidence to date on gabapentin and pregabalin which may support further and con- tinued research and development of the α2δ ligands in disorders characterized by visceral hypersensitivity, such as IBS. The distribution of the α2δ subunit of the voltage-gated cal- cium channel, possible mechanisms of action, pre-clinical data which supports an effect on motor-sensory mechanisms and clinical evidence that points to potential benefits in patients with IBS will be discussed.",
keywords = "αδ ligands, Central sensitization, Gabapentin, Irritable bowel syndrome, Motility, Peripheral sensitization, Pregabalin, Visceral sensitivity",
author = "Gale, {Jeremy D.} and Houghton, {Lesley A.}",
year = "2011",
doi = "10.3389/fphar.2011.00028",
language = "English (US)",
volume = "JUN",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Alpha 2 delta (α2δ) ligands, gabapentin and pregabalin

T2 - What is the evidence for potential use of these ligands in irritable bowel syndrome

AU - Gale, Jeremy D.

AU - Houghton, Lesley A.

PY - 2011

Y1 - 2011

N2 - Irritable bowel syndrome (IBS) is a complex disorder that is characterized by abdominal pain and altered bowel habit, and often associates with other gastrointestinal symptoms such as feelings of incomplete bowel movement and abdominal bloating, and extra-intestinal symptoms such as headache, dyspareunia, heartburn, muscle pain, and back pain. It also frequently coexists with conditions that may also involve central sensitization processes, such as fibromyalgia, irritable bladder disorder, and chronic cough. This review examines the evidence to date on gabapentin and pregabalin which may support further and con- tinued research and development of the α2δ ligands in disorders characterized by visceral hypersensitivity, such as IBS. The distribution of the α2δ subunit of the voltage-gated cal- cium channel, possible mechanisms of action, pre-clinical data which supports an effect on motor-sensory mechanisms and clinical evidence that points to potential benefits in patients with IBS will be discussed.

AB - Irritable bowel syndrome (IBS) is a complex disorder that is characterized by abdominal pain and altered bowel habit, and often associates with other gastrointestinal symptoms such as feelings of incomplete bowel movement and abdominal bloating, and extra-intestinal symptoms such as headache, dyspareunia, heartburn, muscle pain, and back pain. It also frequently coexists with conditions that may also involve central sensitization processes, such as fibromyalgia, irritable bladder disorder, and chronic cough. This review examines the evidence to date on gabapentin and pregabalin which may support further and con- tinued research and development of the α2δ ligands in disorders characterized by visceral hypersensitivity, such as IBS. The distribution of the α2δ subunit of the voltage-gated cal- cium channel, possible mechanisms of action, pre-clinical data which supports an effect on motor-sensory mechanisms and clinical evidence that points to potential benefits in patients with IBS will be discussed.

KW - αδ ligands

KW - Central sensitization

KW - Gabapentin

KW - Irritable bowel syndrome

KW - Motility

KW - Peripheral sensitization

KW - Pregabalin

KW - Visceral sensitivity

UR - http://www.scopus.com/inward/record.url?scp=84856937669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856937669&partnerID=8YFLogxK

U2 - 10.3389/fphar.2011.00028

DO - 10.3389/fphar.2011.00028

M3 - Article

VL - JUN

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - Article 28

ER -